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Objective: Hemodynamic and clinical performances of 21-mm and 23-mm St Jude
Medical Hemodynamic Plus aortic valves (St Jude Medical, Inc, St Paul, Minn)
were compared with those of 21-mm and 23-mm St Jude Medical standard cuff aor-
tic valves in the first such multicenter, prospective, randomized study.
Hemodynamic Plus valves are mechanical, bileaflet prostheses suitable for the
small aortic anulus.
Methods: Patients with 21-mm and 23-mm anulus diameters were randomized to
receive either a Hemodynamic Plus or a standard cuff valve. Postoperatively and at
6 months after the operation, patients underwent 2-dimensional Doppler echocar-
diography. Ejection fraction, cardiac output, peak gradient, mean gradient, effective
orifice area, effective area index, and performance index were calculated.
Postoperative and 6-month echocardiographic measurements and their variations
across observation times were analyzed statistically.
Results: Of the 140 patients enrolled, 5 died at operation and 1 died of aortic dis-
section during the follow-up period. Eight patients were lost to follow-up. A total of
125 patients completed the study. In 1 patient a sewing cuff escaped intraoperative-
ly. At 6 months the 21-mm and 23-mm Hemodynamic Plus valves showed signifi-
cantly lower peak gradients and mean gradients than those of the 21-mm and 23-
mm standard cuff valves. The 21-mm Hemodynamic Plus valves had gradients
similar to those of the 23-mm Hemodynamic Plus valves. The effective orifice area
did not differ significantly between the Hemodynamic Plus and standard cuff valves
at either measurement. No valve mismatch was found in the 4 groups of patients. A
more enhanced decrease of peak gradients and mean gradients and a more enhanced
increase of effective orifice areas, effective area indices, and performance indices
were found across observation times for patients with Hemodynamic Plus valves
compared with those with standard cuff valves.
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Bileaflet mechanical replacement heart valvesaccount for approximately 50% of all heartvalve prostheses currently implanted.1 Themechanical or hemodynamic function ofbileaflet valves is considered to be good andacceptable for most patients. Nevertheless,
concerns remain about the hemodynamic performances of
bileaflet valves implanted in the small aortic anulus.1
To address this issue, St Jude Medical (St Paul, Minn)
has introduced a new model of mechanical bileaflet heart
valve suitable for the small aortic anulus—the St Jude
Medical Hemodynamic Plus (HP) aortic valve. In this new
valve, the sewing cuff has been reconfigured to allow supra-
annular placement. Eliminating the sewing cuff from the
anulus achieves an effectively larger valve orifice with an
equivalent tissue anulus diameter.
The Italian multicenter, prospective, randomized study
was undertaken to evaluate the hemodynamic and clinical
performances of the St Jude Medical HP valve in the aortic
position by comparing it with the St Jude Medical standard
cuff (SC) valve. This was the first study of its kind.
This report presents the results of this controlled study,
providing an in vivo demonstration of the laboratory-
enhanced hemodynamic characteristics of the HP valve and
an assessment of early follow-up results with this valve.
Methods
This controlled study was undertaken by 8 Italian academic units
of cardiac surgery. Study enrollment was 140 patients.
Admission criteria allowed patients with isolated aortic valve
disease (no concomitant mitral, tricuspid, or pulmonic disease)
requiring valve replacement who were also candidates for a
mechanical valve prosthesis. Patients with other associated cardiac
disease, such as coronary artery disease, were not eliminated.
Exclusion criteria eliminated patients requiring aortic valve
replacement on an emergency basis, which did not permit the per-
formance of complete preoperative investigations; patients with
preoperative evaluations indicating other significant cardiovascular
abnormalities, such as aortic aneurysm or dissection, left ventricu-
lar aneurysm, or active endocarditis; as well as patients with a life
expectancy less than 2 years or with chronic liver or kidney failure.
The enrollment period lasted 1 year, and the follow-up period
required for each patient was 6 months. Patients not monitored at
the end of the study were considered lost for the considered out-
come.
The trial protocol was approved by the institutional review
board/ethics committee of each individual participating center.
Informed consent was obtained from each patient before preoper-
ative investigations.
Study Protocol
Patients enrolled were stratified by the model and size of valve
prosthesis they received at operation (21-mm HP, 23-mm HP, 21-
mm SC, or 23-mm SC valve) and were studied accordingly.
Each patient underwent routine preoperative investigations. For
the purposes of this study, postoperative (within 30 days after oper-
ation) and 6-month assessments included a clinical examination
and a transthoracic echocardiogram. The oral anticoagulation level
was kept within an international normalized ratio range of 2.5 and
3.5 in all participating centers.
For each patient, clinical conditions after each visit, echocar-
diographic data, anticoagulation status, and any mortal or morbid
event were recorded on forms for purposes of statistical analysis.
Any complication or death was registered at the time of occurrence
and according to the relevant guidelines for valve surgery.2
Patient Randomization
In the operating theater, once the aorta was opened and the aortic
valve excised, the anulus was sized. Patients with a 21-mm or 23-
mm anulus size were randomized to receive a St Jude Medical HP
or SC valve. Randomization was carried out in a blind manner for
both the patient and surgeon, by opening a sealed opaque envelope
containing the assigned valve type. Envelopes contained random
numbers that were generated by a computer program and were bal-
anced every 4 patients.
Surgical Technique
All operations were performed by means of standard cardiopul-
monary bypass with mild hypothermia. Myocardial protection was
achieved with cold blood antegrade cardioplegia. In patients with
aortic insufficiency, cardioplegic solution was infused directly into
the coronary ostia.
After valve excision, the aortic anulus was completely debrided of
calcium in all patients. All valves were sized with standard sizers. If
randomization assigned an HP valve, the aortic anulus was sized
again with the HP sizer. A close correspondence between the standard
and HP sizers was observed for both 21-mm and 23-mm valve sizes.
All HP valves were implanted at the supra-annular level with
interrupted everting pledget-supported mattress sutures. Each
valve was oriented with its axis perpendicular to the septum. All
the SC valves were implanted at the infra-annular level with the
same implantation technique and valve orientation.
Conclusions: Clinical hemodynamic performances of 21-mm and 23-mm St Jude
Medical Hemodynamic Plus valves correspond closely with those of standard cuff
valves, and gradients are substantially better than those of standard cuff valves of
the same diameter. Therefore, use of this valve may minimize the need for aortic
anulus enlargement. Early follow-up results with the Hemodynamic Plus valves
were excellent, although more time is required to confirm this outcome.
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Concomitant procedures were coronary artery bypass grafting
in 10 cases, closure of a patent ductus arteriosus in 1 case, and atri-
al septal defect in 1 case.
Echocardiography
In each participating center, echocardiograms for the assessment of
functional and hemodynamic valve performances were always car-
ried out by the same echocardiographer who was unaware of the
type of valve implanted.
Doppler echocardiography was obtained from apical and
parasternal long-axis views. The ultrasonography window from
which the highest velocities were obtained was selected and used
for Doppler evaluation. Doppler approach was similar for all par-
ticipating centers. Flow velocity in the left ventricular outflow tract
and across the valve was measured by means of pulsed and con-
tinuous wave Doppler ultrasonography, respectively. The modified
Bernoulli equation was used to calculate peak and mean pressure
gradients across the prosthesis. Color Doppler ultrasonography
was used to visualize and quantify the amount and site of pros-
thetic valve regurgitation.
Doppler Measurements and Calculations
All of the following parameters were collected from each patient:
Cardiac output = time velocity integral × effective 
orifice area × heart rate.
Peak gradient = 4 (V22-V12), where V2 is prosthetic peak veloc-
ity in meters per second measured with continuous-wave Doppler
ultrasonography and V1 is peak velocity proximal to valve in meters
per second, measured with pulsed-wave Doppler ultrasonography.
Mean gradient = 4[(VTI)22 – (VTI)12], where VTI2 is prosthet-
ic velocity time integral measured with continuous-wave Doppler
ultrasonography and VTI1 is proximal velocity time integral meas-
ured with pulsed-wave Doppler ultrasonography, calculated by
online averaging.
Effective orifice area. The effective orifice area (EOA) is an
index of how well a valve design uses its geometric orifice area. It
was calculated with the continuity equation by the simplified peak
velocity method as CSA (PkVLVOT/PkVAo), where CSA is the sub-
valvular cross-sectional area and PkVLVOT and PkVAo are the max-
imal velocity in the left ventricular outflow tract and across the
valve, respectively. The cross-sectional area was calculated by
measuring the left ventricular outflow tract just below the pros-
thetic ring by means of an edge-to-edge method.
Effective area index. The effective area index (EIA) is a meas-
ure of how well the EOA of the valve matches the body surface
area (BSA). It is calculated as EAI = EOA/BSA. This index was
used to detect mismatch between valve size and body surface area.
According to Dumesnil and associates,3 it would appear that an
indexed prosthetic valve area of approximately 0.9 cm2/m2 would
be adequate to minimize the postoperative gradient.
Performance index. The performance index (PI) is a measure
of how effectively the external dimension of the valve is used to
provide forward flow, normalized to the valve size. It is defined as
PI = EOA/geometric area. Most articles provide performance
index, making possible the comparison with other valve types.
Statistical Analysis
As a first step, 1-way analysis of variance for unbalanced blocks was
carried out to compare age, body surface area, aortic crossclamping
time, and cardiopulmonary bypass time by means of the 4 valve types.
TABLE 1. Patient characteristics
Parameter 21-mm SC 21-mm HP 23-mm SC 23-mm HP
N 35 35 35 35
Age (y) 63.6 ± 8 61.3 ± 10 60.6 ± 10 57 ± 15
Sex 
M 14 20 22 27
F 21 15 13 8
Aortic stenosis 24 24 12 17
Stenosis + regurgitation 11 7 11 9
Regurgitation — 4 12 9
NYHA
I — 1 2 —
II 14 14 18 15
III 21 20 12 16
IV — — 3 4
Body surface area (m2) 1.72 ± 0.18 1.74 ± 0.15 1.78 ± 0.21 1.78 ± 0.15
CPB time (min) 99.5 ± 0.18 107 ± 35 93.4 ± 33 84.3 ± 25
Crossclamping time (min) 75.7 ± 24 76.4 ± 24 69 ± 22 64 ± 16
N, Number of patients enrolled in the study; SC, St Jude Medical standard cuff valve; HP, St Jude Medical Hemodynamic Plus valve; NYHA, New York Heart
Association; CPB, Cardiopulmonary bypass. There was no significant difference in age (P = .22), body surface area (P = .40), and crossclamping time (P =
.35). Difference in CPB time reached statistical significance (P = .039).
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Second, analysis of variance was applied to study performance
characteristics of the 4 valve types, separately in the 2 observation
times (postoperatively and 6 months after the operation). In this
framework, orthogonal comparisons were carried out for the 4
blocks and for linear contrasts regarding specific couplings (21-
mm HP vs 21-mm SC; 21-mm HP vs 23-mm SC; and 23-mm HP
vs 23-mm SC).
As a third step, the Wilcoxon rank test for dependent samples
was applied, accounting for variation from both observation times
within each of the 4 valve types.
All data were expressed as mean ± standard deviation (SD).
Confidence intervals were calculated at 95% of significance.
Results
A total of 140 patients were enrolled in the study. Their
demographics and clinical characteristics are shown in
Table 1. Of these, 5 patients (3.5%) died at operation (30-
day mortality); causes of death were low output syndrome
in 4 patients and renal failure in 1 patient. There was an
Surgery for Acquired Cardiovascular Disease Vitale et al
TABLE 2. Postoperative echocardiographic data
21-mm SC 21-mm HP 23-mm SC 23-mm HP
Parameter (n = 27) P* (n = 35) P† (n = 30) P‡ (n = 33)
CO (L/m) 5.84 ± 1.8 .016 4.32 ± 1.7 .0004 6.51 ± 2.7 .019 4.97 ± 1.9
EF 0.56 ± 0.9 .51 0.54 ± 0.9 .98 0.54 ± 0.9 .67 0.53 ± 0.1
Peak gradient (mm Hg) 28.0 ± 9.9 .005 21.0 ± 10 .0059 27.5 ± 7.3 .0034 20.2 ± 8.8
Mean gradient (mm Hg) 20.2 ± 4.7 .5 18.8 ± 10 .7 19.5 ± 5.3 .025 14.9 ± 5.3
EOA (cm2) 1.53 ± 0.5 .2 1.56 ± 0.4 .011 1.66 ± 0.5 .72 1.60 ± 0.6
EAI (cm2) 0.90 ± 0.3 .074 0.90 ± 0.2 .7 0.94 ± 0.2 .69 0.90 ± 0.3
PI (cm2) 0.64 ± 0.2 .08 0.61 ± 0.2 .8 0.64 ± 0.2 .2 0.55 ± 0.2
Data are expressed as mean ± standard deviation. The number of patients in each group is indicated in parentheses. SC, St Jude Medical standard cuff
valve; HP, St Jude Medical Hemodynamic Plus valve; CO, cardiac output; EF, ejection fraction; EOA, effective orifice area; EAI, effective area index; PI, per-
formance index.
*P value, 21-mm SC vs 21-mm HP valves.
†P value, 21-mm HP vs 23-mm SC valves.
‡P value, 23-mm SC vs 23-mm HP valves.
Figure 1. Serial changes of peak and mean transvalvular gradients over time within the 4 groups. The P values
express the comparisons between postoperative and 6-month observation times. MG, Mean gradients; PG, peak
gradients.
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intraoperative complete detachment of a 23-mm HP valve
sewing cuff resulting from disruption of the cuff’s thread
windings caused by a suture needle. The patient received a
CarboMedics valve (Sulzer Carbomedics, Inc, Austin, Tex)
as described elsewhere.4 In the follow-up, 1 patient with a
23-mm SC valve had acute aortic dissection 2 months after
valve replacement and died at reoperation. Of the remaining
133 patients, 125 patients completed the 6-month follow-up,
but 8 patients were censored because they refused to under-
go evaluation at 6 months. Echocardiographic data and clin-
ical results reported here are those obtained from the 125
patients.
Echocardiography
Postoperative and 6-month echocardiographic measure-
ments (mean ± SD), together with P values for comparisons
between valve types, are presented in Tables 2 and 3, respec-
tively. Figure 1 shows changes in peak and mean trans-
TABLE 3. Six-month echocardiographic data
21-mm SC 21-mm HP 23-mm SC 23-mm HP
Parameter (n = 27) P* (n = 35) P† (n = 30) P‡ (n = 33)
CO (L/m) 5.43 ± 1.6 .14 4.66 ± 1.9 .0022 6.17 ± 1.9 .011 4.82 ± 1.5
EF 0.58 ± 0.8 .17 0.62 ± 0.8 .53 0.66 ± 0.6 .19 0.57 ± 0.9
Peak gradient (mm Hg) 24.6 ± 6.9 .0003 16.3 ± 8.4 .0001 24.7 ± 9.5 .0005 16.8 ± 7.3
Mean gradient (mm Hg) 17.8 ± 5.2 .001 12.6 ± 6.5 .001 17.5 ± 6 .0008 12.1 ± 4.2
EOA (cm2) 1.49 ± 0.4 .6 1.57 ± 0.6 .45 1.67 ± 0.5 .9 1.69 ± 0.5
EAI (cm2) 0.87 ± 0.2 .74 0.90 ± 0.3 .62 0.94 ± 0.3 .75 0.97 ± 0.3
PI (cm2) 0.61 ± 0.2 .88 0.6 ± 0.2 .062 0.7 ± 0.2 .05 0.58 ± 0.2
Data are expressed as mean ± standard deviation. The number of patients in each group is indicated in parentheses. SC, St Jude Medical standard cuff
valve; HP, St Jude Medical Hemodynamic Plus valve; CO, cardiac output; EF, ejection fraction; EOA, effective orifice area; EAI, effective area index; PI, per-
formance index.
*P value, 21-mm SC vs 21-mm HP valves.
†P value, 21-mm HP vs 23-mm SC valves.
‡P value, 23-mm SC vs 23-mm HP valves.
Figure 2. Serial changes of valve effective orifice areas (EOA) over time within the 4 groups. The P values express
the comparisons between postoperative and 6-month observation times.
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valvular gradients between postoperative and 6-month
measurements within each of the 4 groups, whereas Figure
2 depicts serial changes of effective orifice areas.
Peak Gradient
At both observation times, the 21-mm and 23-mm HP
valves showed lower gradients than the SC valves of the
same size. In particular, the 21-mm HP valves had lower
gradients than the 23-mm SC valves. Interestingly, the 21-
mm HP valves had gradients similar to those of the 23-mm
HP valves. All gradients decreased over time in each group,
and all these differences were statistically significant
between the 2 observation times.
Mean Gradient
Postoperatively, the 21-mm SC and 21-mm HP valves had
equal mean gradients, whereas the 23-mm HP valve had a
slightly lower gradient than 23-mm SC valve. At 6 months
both the 21- and 23-mm HP valves had lower gradients than
the SC valves. All gradients decreased over time in each
group, and all the differences reached statistical signifi-
cance, except for those of the 23-mm SC valves.
Effective Orifice Area 
There was not a statistically significant difference in effec-
tive orifice areas between the groups. At postoperative obser-
vation, the effective orifice areas of the 21-mm HP valves
were slightly larger than those of the 21-mm SC valves and
remained larger at the 6-month measurement. The 23-mm
HP and SC valves showed approximately the same effective
orifice areas. The effective orifice areas of the 23-mm HP
valves increased over time, and the difference between the 2
observation times was statistically significant. The effective
orifice areas of the 21-mm SC valves decreased at the 6-
month measurement, and the difference was significant. The
areas of the 23-mm SC valves increased only slightly, and
the difference did not reach statistical significance.
Effective Area Index
At postoperative measurement, effective orifice area
matched for all groups with respect to valve size and body
surface area at postoperative and 6-month measurements.
The effective area indices for the 23-mm HP valves
increased at 6 months, and the difference between the 2
observations reached statistical significance (P = .004). The
effective area indices for the 21-mm SC valves decreased
slightly at 6 months, and the difference was significant (P =
.0008). The effective area indices for the 23-mm SC valves
did not change across time (P = .93).
Performance Index
Postoperatively, the 23-mm HP valves showed a lower per-
formance index than the 23-mm SC valves, the differences
not being statistically significant. Performance indices for
the 23-mm HP valves and the 23-mm SC valves increased
over time, but the difference was statistically significant
only for the 23-mm SC valves (P = .003). The performance
index for the 21-mm HP valves did not change over time (P
= .2). The performance index for the 21-mm SC valves
decreased slightly at 6 months, and this difference was sig-
nificant (P = .0008).
Follow-up
At the end of 6 months of follow-up, no valve thrombosis,
thromboembolic events, or anticoagulation-related hemor-
rhages were observed. All patients are well with a satisfac-
tory quality of life.
Discussion
As in most practices nowadays, our population was largely
composed of patients who required aortic valve replacement
for severe calcified valve stenosis. Despite a reduced cuff
thickness, all surgeons found the St Jude Medical HP valve
relatively easy to implant in the supraannular position.
Peak and mean transvalvular gradients are still the
parameters most frequently used to characterize a pros-
thetic heart valve.5 In our comparison with the St Jude
Medical SC valves of the same outer diameter, both the
21-mm and 23-mm HP valves demonstrated much lower
peak and mean transvalvular gradients both postopera-
tively and at 6 months after the operation. Furthermore,
the 21-mm HP valves showed gradients lower than those
of the 23-mm SC valves. The 21-mm valves had equal
mean gradients at discharge. At 6 months the 21-mm HP
valve had peak and mean gradients similar to those of the
23-mm HP valves, thereby showing the most beneficial
size/gradient relationship.
Doppler echocardiography is the most commonly used
method of follow-up for patients with prosthetic heart
valves.6 Measurements of pressure gradients across differ-
ent types of bioprosthetic and mechanical valves are report-
ed to correlate well with catheter-derived gradients.5
Although bileaflet valves have a central flow and should
allow an accurate measurement of pressure gradients, the
presence of pressure recovery and high localized pressure
gradients might cause an overestimation of gradients com-
pared with the catheter-derived pressure gradient as found
by Baumgartner and associates7 in St Jude Medical valves.
Therefore, we should be aware the Doppler-defined gradi-
ents of our study could be slight overestimations of catheter-
derived gradients. With respect to gradient variations
between postoperative and 6-month time points, decreases
were observed within each group and were more enhanced
for the 21-mm HP valves.
With regard to effective orifice area, slightly (but not sig-
nificantly) larger valve areas were found for the HP valves
Surgery for Acquired Cardiovascular Disease Vitale et al
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than for SC valves at 6 months. In our series, the effective
orifice areas of 21-mm HP valves at 6 months were smaller
than those reported by Carrel and associates.8 In vivo effec-
tive orifice areas of 23-mm HP valves have not yet appeared
in the literature, to the best of our knowledge. Another inter-
esting finding of our study was the proven increase of valve
areas over time for 23-mm HP valves. On the other hand,
the effective orifice areas of 21-mm and 23-mm SC valves
did not increase over time. All observed increases developed
quite rapidly, within 6 months after operation. This observa-
tion contrasts with the findings of Henneke, Pongratz, and
Bachmann,9 who noted that a postoperative interval of less
than 1 year did not alter the Doppler-derived measurements
of effective orifice area.
With regard to effective area indices, the 23-mm HP
valve indices were higher than those of 23-mm SC valve
indices at 6 months. On the other hand, at postoperative
measurement, the effective area indices for the 21-mm HP
valves were similar to those of the 21-mm SC valves, but
were higher at 6 months. The effective area indices for the
21-mm SC valves did not change across the 2 observation
times. All the observed increases were a result of increases
in effective orifice areas because all body surface areas
remained constant at both observation times. Moreover, the
body surface areas of our patients were above 1.7 m2.
On the basis of the assumption that an effective area
index of 0.9 cm2/m2 is the requirement for a patient with an
aortic prosthetic valve and that this value was calculated in
patients with tilting disc and tissue valves,3 all our patients
showed a satisfactory prosthesis-patient match.
Several studies have examined the impact of small aortic
prostheses on long-term results. In a series of 254 patients,
Kratz and others10 implanted 19-mm and 21-mm valves in
115 patients. In comparison with the overall results, the
implantation of a small aortic valve was followed by a
somewhat higher incidence of late sudden death in patients
with body surface areas of 1.9 m2. According to Czer and
associates,11 implantation of smaller valves did not affect
short-term hospital results. However, in this series, results
were limited to patients with body surface areas of less than
1.7 m2. Jaffe,12 Burkhardt,13 and their colleagues have sug-
gested that peak aortic pressure gradients up to 40 mm Hg
did not bear any clinical significance for up to a decade in
the majority of patients.
Performance indices were almost comparable between
the groups. Our results of 0.56 to 0.71 cm2 were similar to
those of other reports on St Jude Medical valves.8
Furthermore, a performance index between 0.37 and 0.44
cm2 has been reported for small Björk-Shiley valves (Shiley,
Inc, Irvine, Calif), and a performance index of 0.53 cm2 has
been reported for the 21-mm Medtronic-Hall mechanical
valve (Medtronic, Inc, Minneapolis, Minn).14 Time-related
increases in performance indices were observed for the 21-
mm HP valves. As with effective area indices, these increas-
es were due to improvement in effective orifice areas over
time.
During the early follow-up of the 125 patients who com-
pleted the study, no valve-related morbidity or mortality was
observed. Therefore, the results of our study with the St
Jude Medical HP valve in the aortic position confirm the
satisfactory results obtained with St Jude Medical SC
valves.12,13
All the parameters we considered were the same param-
eters presented in several studies on heart valve prosthe-
ses.6-8,14-16 Furthermore, our study was the first with a mul-
ticenter, controlled and randomized protocol that was
carried out on the St Jude Medical HP aortic valve.
Nonetheless, there may be bias in our study. Differences in
cardiac output were observed that may have caused the dif-
ference in transvalvular gradients. Cross-sectional areas of
the valves were measured with an edge-to-edge method, and
in patients with a hypertrophic ventricular septum this may
reduce effective orifice areas.
Therefore, several conclusions can be drawn from our
study. St Jude Medical 21-mm and 23-mm HP valves have
demonstrated better hemodynamic characteristics than St
Jude Medical SC valves. These positive results confirm lab-
oratory findings of lower pressure drops and energy losses
for St Jude Medical HP valves.1 All the considered parame-
ters demonstrated, at both observation times, that perfor-
mances of the 21-mm and 23-mm HP valves were substan-
tially better than those of the SC valves of the same
diameters and were comparable with those of the SC valves
with larger external diameters. Both a more enhanced
decrease of transvalvular pressure gradients and a more
enhanced increase of valve areas were observed for the HP
valves versus the SC valves across observation times.
In particular, the 21-mm HP valves showed low gradi-
ents, even similar to those of 23-mm HP valves. With this in
mind, the 21-mm HP valve may be considered a very satis-
factory prosthetic valvular device in the small aortic anulus.
Implantation of a 21-mm HP valve should avoid forcing a
larger valve into a tight anulus or spare an aortic anulus
enlargement. The use of the 21-mm HP valve would ease
the procedure and reduce mortality and morbidity related to
the longer operative time.
Results of early follow-up with the St Jude Medical HP
valves were excellent. Nevertheless, a longer follow-up is
desirable to confirm this outcome.
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